Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
Rosalba Torrisi(IRCCS Humanitas Research Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), Rita De Sanctis(Humanitas University), Emilia Marrazzo(Fondazione Humanitas per la Ricerca), Elisa Agostinetto(Université Libre de Bruxelles), Agnese Losurdo(Humanitas University), Corrado Tinterri(Humanitas University), Giovanna Masci(Humanitas University)
Cited by 63
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532